Article Versions Notes

Pelizzari G, Basile D, Zago S, Lisanti C, Bartoletti M, Bortot L, Vitale MG, Fanotto V, Barban S, Cinausero M, et al. Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker. Cancers. 2019; 11(9):1243. https://doi.org/10.3390/cancers11091243

Pelizzari, Giacomo, Debora Basile, Silvia Zago, Camilla Lisanti, Michele Bartoletti, Lucia Bortot, Maria Grazia Vitale, Valentina Fanotto, Serena Barban, Marika Cinausero, and et al. 2019. "Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker" Cancers 11, no. 9: 1243. https://doi.org/10.3390/cancers11091243

Pelizzari, G., Basile, D., Zago, S., Lisanti, C., Bartoletti, M., Bortot, L., Vitale, M. G., Fanotto, V., Barban, S., Cinausero, M., Bonotto, M., Gerratana, L., Mansutti, M., Curcio, F., Fasola, G., Minisini, A. M., & Puglisi, F. (2019). Lactate Dehydrogenase (LDH) Response to First-Line Treatment Predicts Survival in Metastatic Breast Cancer: First Clues for a Cost-Effective and Dynamic Biomarker. Cancers, 11(9), 1243. https://doi.org/10.3390/cancers11091243